BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22814366)

  • 1. Serum thyroglobulin level measured after thyroxine withdrawal is useful to predict further recurrence in whole body scan-negative papillary thyroid cancer patients after reoperation.
    Park DJ; Lim JA; Kim TH; Choi HS; Ahn HY; Lee EK; Lee YJ; Kim KW; Park YJ; Yi KH; Cho BY
    Endocr J; 2012; 59(11):1021-30. PubMed ID: 22814366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reoperative lymph node dissection for recurrent papillary thyroid cancer and effect on serum thyroglobulin.
    Hughes DT; Laird AM; Miller BS; Gauger PG; Doherty GM
    Ann Surg Oncol; 2012 Sep; 19(9):2951-7. PubMed ID: 22526913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-week thyroxine withdrawal thyroglobulin stimulation screening test to detect low-risk residual/recurrent well-differentiated thyroid carcinoma.
    Golger A; Fridman TR; Eski S; Witterick IJ; Freeman JL; Walfish PG
    J Endocrinol Invest; 2003 Oct; 26(10):1023-31. PubMed ID: 14759077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The value of diagnostic whole-body scanning and serum thyroglobulin in the presence of elevated serum thyrotropin during follow-up of anti-thyroglobulin antibody-positive patients with differentiated thyroid carcinoma who appeared to be free of disease after total thyroidectomy and radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Lacerda RX; dos Santos DA; Calsolari MR
    Thyroid; 2012 Feb; 22(2):113-6. PubMed ID: 22224815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
    Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
    Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serial post-surgical stimulated and unstimulated highly sensitive thyroglobulin measurements in low- and intermediate-risk papillary thyroid carcinoma patients not receiving radioactive iodine.
    Kashat L; Orlov S; Orlov D; Assi J; Salari F; Walfish PG
    Endocrine; 2016 Nov; 54(2):460-466. PubMed ID: 27189148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Papillary Thyroid Carcinoma Recurrence: Low Yield of Neck Ultrasound With an Undetectable Serum Thyroglobulin Level.
    Epstein S; McEachern R; Khot R; Padia S; Patrie JT; Itri JN
    J Ultrasound Med; 2018 Oct; 37(10):2325-2331. PubMed ID: 29498418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Prates BS; Silva LC; Calsolari MR
    Thyroid; 2012 Nov; 22(11):1140-3. PubMed ID: 23050786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low postoperative nonstimulated thyroglobulin as a criterion to spare radioiodine ablation.
    Mourão GF; Rosario PW; Calsolari MR
    Endocr Relat Cancer; 2016 Jan; 23(1):47-52. PubMed ID: 26503963
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disease outcomes and nodal recurrence in patients with papillary thyroid cancer and lateral neck nodal metastases.
    O'Neill CJ; Coorough N; Lee JC; Clements J; Delbridge LW; Sippel R; Sywak MS; Chen H; Sidhu SB
    ANZ J Surg; 2014 Apr; 84(4):240-4. PubMed ID: 23316684
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is stimulation of thyroglobulin (Tg) useful in low-risk patients with thyroid carcinoma and undetectable Tg on thyroxin and negative neck ultrasound?
    Rosário PW; Borges MA; Fagundes TA; Franco AC; Purisch S
    Clin Endocrinol (Oxf); 2005 Feb; 62(2):121-5. PubMed ID: 15670185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
    Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in Serum Thyroglobulin Levels After Lobectomy in Patients with Low-Risk Papillary Thyroid Cancer.
    Park S; Jeon MJ; Oh HS; Lee YM; Sung TY; Han M; Han JM; Kim TY; Chung KW; Kim WB; Shong YK; Kim WG
    Thyroid; 2018 Aug; 28(8):997-1003. PubMed ID: 29845894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Impact of Detectable Antithyroglobulin Antibodies Below the Reference Limit (Borderline) in Patients with Papillary Thyroid Carcinoma with Undetectable Serum Thyroglobulin and Normal Neck Ultrasonography After Ablation: A Prospective Study.
    Côrtes MCS; Rosario PW; Oliveira LFF; Calsolari MR
    Thyroid; 2018 Feb; 28(2):229-235. PubMed ID: 29325506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma.
    Frasoldati A; Pesenti M; Gallo M; Caroggio A; Salvo D; Valcavi R
    Cancer; 2003 Jan; 97(1):90-6. PubMed ID: 12491509
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence.
    Rosario PW; Furtado Mde S; Mineiro Filho AF; Lacerda RX; Calsolari MR
    Thyroid; 2012 Nov; 22(11):1165-9. PubMed ID: 23050784
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
    Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
    Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma.
    Ringel MD; Balducci-Silano PL; Anderson JS; Spencer CA; Silverman J; Sparling YH; Francis GL; Burman KD; Wartofsky L; Ladenson PW; Levine MA; Tuttle RM
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4037-42. PubMed ID: 10566646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individualized Follow-Up Strategy for Patients with an Indeterminate Response to Initial Therapy for Papillary Thyroid Carcinoma.
    Oh HS; Ahn JH; Song E; Han JM; Kim WG; Kim TY; Kim WB; Shong YK; Jeon MJ
    Thyroid; 2019 Feb; 29(2):209-215. PubMed ID: 30384812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.